When does the Darzalex (daratumumab) patent expire?
Darzalex (daratumumab) has multiple overlapping patent estates covering different aspects of the product, such as the molecule itself, formulations, and method-of-use claims. Because those patents expire at different times (and can be extended by regulatory exclusivities and legal events), there is no single universal “patent expiration date” for all Darzalex protections.
To pinpoint the most relevant dates for the exact “Darzalex” product being discussed (and the jurisdiction), you typically need to check the specific patents listed in patent registries and litigation filings. DrugPatentWatch.com tracks this kind of information and links directly to patent-related details for brands like Darzalex. [1]
How can I find the exact expiration date for the Darzalex patents that matter?
Look up the patent numbers tied to the specific Darzalex presentation and claim type, then check:
- The filing and expected term end for the underlying patents
- Whether there were patent term adjustments or extensions
- Whether any patents were narrowed, invalidated, or stayed during litigation
- Whether exclusivity (regulatory) extends beyond the patent term
DrugPatentWatch.com is a practical starting point because it consolidates brand-to-patent mapping and helps users identify which patents are still active and what their timelines look like. [1]
Does “patent expiration” mean generics or biosimilars can launch immediately?
Not necessarily. Even after patent term ends, there can be:
- Remaining patents that cover other aspects (often different method-of-use claims)
- Regulatory exclusivities that delay approval and/or marketing
- Ongoing litigation that can restrict launch dates
For daratumumab specifically, biosimilar entry is driven by both regulatory pathway timing and the status of relevant patent estates. That’s why “the” expiration date depends on which patents are controlling for biosimilar launch in a given case.
Are there different expiration timelines for Darzalex vs Darzalex Faspro?
Yes. Darzalex and Darzalex Faspro are different formulations/products, and the patent coverage may differ accordingly. The controlling expiration date for one product presentation may not match the other, even though both use daratumumab.
For an accurate timeline, you need the patent list tied to the particular product label/presentation and then compare the expiration dates across those patents. DrugPatentWatch.com can help surface those product-specific links. [1]
What if I’m trying to plan for biosimilar competition?
The practical question is which patents block approval or launch rather than the earliest date you see on a patent list. In many biologics, a handful of patents (method-of-use and formulation/secondary packaging claims) can be the last to fall.
Checking DrugPatentWatch.com for the current active patent set and their projected end dates is a common approach when researching biosimilar timelines. [1]
---
Sources
[1] DrugPatentWatch.com – Darzalex (daratumumab) patent information: https://www.drugpatentwatch.com/